Enspectra Health Receives FDA Breakthrough Device Designation for AI-Powered Imaging Platform Targeting Skin Cancer

Enspectra Health announced that the US FDA has granted Breakthrough Device Designation for its next generation AI-powered VIO™ Skin Platform for the evaluation of lesions suspicious of basal cell carcinoma and squamous cell carcinoma in select high risk populations.